Webinar information
Webinar Access Required
Please fill out the form below to access this past webinar.
Fill the form to watch the webinarIf you are having trouble viewing the webinar video, please try clearing your browser’s cookies/cache.
Epilepsy is one of the most common childhood-onset neurological conditions with a genetic basis. Genetic testing is an effective way to determine the underlying cause of early-onset seizures and provide effective and tailored treatment.
The Paediatric Epilepsy? Look Beyond Program is a no-cost genetic testing program for individuals in Europe and the Middle East. It is currently available for children whose first unprovoked seizure occurs between 2 and 4 years of age (24-48 months). This program aims to improve early detection of neurodegenerative diseases that begin in early childhood and often initially present with seizures.
In this webinar, presented by Executive Medical Director Tero-Pekka Alastalo, MD, PhD, we will provide an overview of how the program works and evaluate the benefits of genetic testing for paediatric epilepsy patients.
Webinar objectives:
- Discuss the benefits of genetic testing for early-onset epilepsy
- Introduce the program and why it is the best choice for paediatric epilepsy patients
- Describe ordering and how to participate in the program
- Examine the panel used in this program and its strengths
- Give an overview of Blueprint’s experience with epilepsy patients and genetic testing
- Evaluate data privacy and data sharing policies
Speakers
Tero-Pekka Alastalo
Tero-Pekka is the Executive Director of Medical, and also a co-founder at Blueprint Genetics. He is based in San Francisco and holds various responsibilities in the North American operations of the company. Tero-Pekka has an MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. During his 3-year postdoctoral training at Stanford University School of Medicine, he focused on the molecular genetic mechanisms of cardiovascular disease.
More details here